Trimetazidine in coronary heart disease patients: mechanism of action and controlled trials’ results
Metabolic cardioprotection is an important part of treating patients with coronary heart disease (CHD). The most widely used drug in this group is trimetazidine. Its mechanism of action is based on fatty acids metabolism inhibition, glucose oxidation activation, intracellular ATP deficit prevention....
Gespeichert in:
| Hauptverfasser: | , , |
|---|---|
| Format: | Artigo |
| Sprache: | Russo |
| Veröffentlicht: |
«SILICEA-POLIGRAF» LLC
2005-04-01
|
| Schriftenreihe: | Кардиоваскулярная терапия и профилактика |
| Schlagworte: | |
| Online-Zugang: | https://cardiovascular.elpub.ru/jour/article/view/938 |
| Tags: |
Keine Tags, Fügen Sie das erste Tag hinzu!
|